SARS-CoV-2 omicron sub-lineages differentially modulate interferon response in human lung epithelial cells.
Innate immunity
Interferon antagonism
ORF6
Omicron
SARS-CoV-2
Journal
Virus research
ISSN: 1872-7492
Titre abrégé: Virus Res
Pays: Netherlands
ID NLM: 8410979
Informations de publication
Date de publication:
15 07 2023
15 07 2023
Historique:
received:
09
01
2023
revised:
11
05
2023
accepted:
14
05
2023
medline:
9
6
2023
pubmed:
17
5
2023
entrez:
16
5
2023
Statut:
ppublish
Résumé
Although most of the attention was focused on the characterization of changes in the Spike protein among variants of SARS-CoV-2 virus, mutations outside the Spike region are likely to contribute to virus pathogenesis, virus adaptation and escape to the immune system. Phylogenetic analysis of SARS-CoV-2 Omicron strains reveals that several virus sub-lineages could be distinguished, from BA.1 up to BA.5. Regarding BA.1, BA.2 and BA.5, several mutations concern viral proteins with antagonistic activity to the innate immune system, such as NSP1 (S
Identifiants
pubmed: 37192725
pii: S0168-1702(23)00096-5
doi: 10.1016/j.virusres.2023.199134
pmc: PMC10191105
pii:
doi:
Substances chimiques
Interferons
9008-11-1
Interferon-beta
77238-31-4
Ataxia Telangiectasia Mutated Proteins
EC 2.7.11.1
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
199134Informations de copyright
Copyright © 2023. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors declare the following financial interests/personal relationships which may be considered as potential competing interests.
Références
Nature. 2021 Dec;600(7887):21
pubmed: 34824381
Cell Host Microbe. 2016 Feb 10;19(2):181-93
pubmed: 26867177
Cell Biosci. 2022 Mar 22;12(1):36
pubmed: 35317858
Signal Transduct Target Ther. 2020 Dec 28;5(1):299
pubmed: 33372174
Arch Microbiol. 2021 Jul;203(5):1943-1951
pubmed: 33682075
Front Immunol. 2014 Jul 23;5:342
pubmed: 25101084
Signal Transduct Target Ther. 2022 Feb 10;7(1):45
pubmed: 35145066
PLoS Pathog. 2021 Aug 26;17(8):e1009800
pubmed: 34437657
mBio. 2021 Apr 13;12(2):
pubmed: 33849972
Commun Biol. 2021 Jun 10;4(1):715
pubmed: 34112887
Viruses. 2012 May;4(5):901-23
pubmed: 22754655
Viruses. 2021 Jul 23;13(8):
pubmed: 34452305
Science. 2020 Sep 4;369(6508):1249-1255
pubmed: 32680882
Nature. 2022 Feb;602(7897):487-495
pubmed: 34942634
Viruses. 2022 Jun 11;14(6):
pubmed: 35746745
Int J Surg. 2022 Mar;99:106261
pubmed: 35167986
J Chem Inf Model. 2022 Jan 24;62(2):412-422
pubmed: 34989238
Int J Infect Dis. 2022 Jan;114:268-272
pubmed: 34863925
Emerg Microbes Infect. 2020 Dec;9(1):1418-1428
pubmed: 32529952
Nat Rev Immunol. 2020 Jul;20(7):397-398
pubmed: 32457522
Nature. 2021 Jun;594(7862):240-245
pubmed: 33979833
Int J Surg. 2022 Jul;103:106698
pubmed: 35690362
J Virol. 2021 Jun 10;95(13):e0026621
pubmed: 34110264
J Med Virol. 2022 May;94(5):1777-1779
pubmed: 34964502
Cells. 2021 Jun 20;10(6):
pubmed: 34202997
Comput Struct Biotechnol J. 2021;19:4217-4225
pubmed: 34336145
Int J Surg. 2022 Mar;99:106581
pubmed: 35202859
Cell Mol Immunol. 2021 Apr;18(4):945-953
pubmed: 33637958
Cell Rep. 2020 Oct 6;33(1):108234
pubmed: 32979938
Nat Struct Mol Biol. 2020 Oct;27(10):959-966
pubmed: 32908316
J Korean Med Sci. 2022 Jan 17;37(3):e31
pubmed: 35040299
Cell. 2020 May 28;181(5):1036-1045.e9
pubmed: 32416070
Commun Biol. 2022 May 19;5(1):483
pubmed: 35590097
Cell Rep. 2021 Oct 19;37(3):109841
pubmed: 34624207
Nat Commun. 2020 Jul 30;11(1):3810
pubmed: 32733001
Viruses. 2020 Dec 30;13(1):
pubmed: 33396605
Nature. 2022 Mar;603(7902):715-720
pubmed: 35104836
Proc Natl Acad Sci U S A. 2020 Nov 10;117(45):28344-28354
pubmed: 33097660
Science. 2020 Aug 7;369(6504):718-724
pubmed: 32661059
Eur Rev Med Pharmacol Sci. 2021 Dec;25(24):8019-8022
pubmed: 34982466